BioNTech SE (ETR:22UA)
101.70
+6.60 (6.94%)
At close: Aug 21, 2026
BioNTech SE Revenue
BioNTech SE had revenue of 145.80M EUR in the quarter ending June 30, 2026, a decrease of -56.99%. This brings the company's revenue in the last twelve months to 2.43B, down -0.35% year-over-year. In the year 2025, BioNTech SE had annual revenue of 3.05B with 5.63% growth.
Revenue (ttm)
2.43B
Revenue Growth
-0.35%
P/S Ratio
9.47
Revenue / Employee
339.44K
Employees
7,807
Market Cap
25.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.05B | 162.80M | 5.63% |
| Dec 31, 2024 | 2.89B | -1.03B | -26.31% |
| Dec 31, 2023 | 3.92B | -13.39B | -77.33% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | 108.60M | -18.98M | -14.87% |
| Dec 31, 2018 | 127.58M | 65.98M | 107.11% |
| Dec 31, 2017 | 61.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.38B |
| Fresenius SE & Co. KGaA | 23.28B |
| Siemens Healthineers AG | 23.17B |
| Merck KGaA | 21.14B |
| Fresenius Medical Care AG | 19.43B |
| Sartorius Aktiengesellschaft | 3.58B |
| Fielmann Group AG | 2.44B |
| Carl Zeiss Meditec AG | 2.18B |
BioNTech SE News
- 3 days ago - BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 - GlobeNewsWire
- 19 days ago - BioNTech SE Earnings Call Transcript: Q2 2026 - Transcripts
- 19 days ago - BioNTech SE Earnings release: Q2 2026 - Filings
- 19 days ago - BioNTech SE Slides: Q2 2026 - Filings
- 19 days ago - Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings - Barrons
- 19 days ago - BioNTech lowers 2026 sales outlook as COVID vaccine demand softens - Reuters
- 19 days ago - BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update - GlobeNewsWire
- 20 days ago - BioNTech says Sobi's Oelkers will replace Sahin as CEO - Reuters